Figure 1.

Timing of data documentation in the Global ETNA noninterventional studies. ^aFollow‐up time for ETNA‐AF EU, Japan, and East and Southeast Asia is 4, 2, and 2 years, respectively; ^bFollow‐up time for ETNA‐VTE EU, Japan, and East and Southeast Asia is 1.5, 1, and 1 years, respectively; ^cETNA‐AF only; ^dETNA‐VTE only; ^eInvestigator reported bleeding, stroke, SEE, TIA, ACS, HF, MI, VTE (and recurrent DVT and PE in ETNA‐VTE), and death. ACS, acute coronary syndrome; AF, atrial fibrillation; DVT, deep vein thrombosis; ETNA, Edoxaban Treatment in routine cliNical prActice; HF, heart failure; MI, myocardial infarction; PE, pulmonary embolism; SEE, systemic embolic event; TIA, transient ischemic attack; VTE, venous thromboembolism